Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11457) 11457
Publication (907) 907
Book Review (75) 75
Book Chapter (34) 34
Dissertation (4) 4
Magazine Article (4) 4
Book / eBook (3) 3
Conference Proceeding (2) 2
Government Document (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10387) 10387
female (7356) 7356
male (6787) 6787
remission induction (6237) 6237
middle aged (6032) 6032
adult (5471) 5471
oncology (5422) 5422
index medicus (5333) 5333
aged (4777) 4777
antineoplastic combined chemotherapy protocols - therapeutic use (4573) 4573
chemotherapy (3428) 3428
treatment outcome (3285) 3285
antineoplastic combined chemotherapy protocols - adverse effects (3257) 3257
hematology (3154) 3154
cancer (2890) 2890
adolescent (2054) 2054
induction (1950) 1950
induction chemotherapy (1728) 1728
therapy (1678) 1678
survival rate (1673) 1673
combined modality therapy (1607) 1607
disease-free survival (1586) 1586
prognosis (1469) 1469
aged, 80 and over (1451) 1451
care and treatment (1411) 1411
follow-up studies (1368) 1368
retrospective studies (1339) 1339
neoplasm staging (1333) 1333
survival analysis (1257) 1257
child (1237) 1237
drug administration schedule (1211) 1211
antineoplastic combined chemotherapy protocols - administration & dosage (1101) 1101
cisplatin - administration & dosage (1073) 1073
antineoplastic agents - therapeutic use (1072) 1072
transplantation (1052) 1052
survival (1023) 1023
young adult (1006) 1006
radiotherapy (997) 997
antineoplastic agents - adverse effects (972) 972
recurrence (957) 957
child, preschool (929) 929
risk factors (874) 874
analysis (864) 864
research (854) 854
leukemia, myeloid, acute - drug therapy (850) 850
medicine & public health (849) 849
cisplatin (843) 843
cytarabine - administration & dosage (832) 832
cyclophosphamide - administration & dosage (830) 830
trial (828) 828
health aspects (821) 821
time factors (782) 782
hematology, oncology and palliative medicine (781) 781
animals (779) 779
leukemia (757) 757
prospective studies (744) 744
pharmacology & pharmacy (730) 730
doxorubicin - administration & dosage (703) 703
etoposide - administration & dosage (693) 693
apoptosis (688) 688
surgery (686) 686
fluorouracil - administration & dosage (670) 670
lung neoplasms - drug therapy (657) 657
dose-response relationship, drug (649) 649
vincristine - administration & dosage (635) 635
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (629) 629
infant (624) 624
carcinoma (611) 611
antineoplastic agents - administration & dosage (603) 603
children (588) 588
cisplatin - adverse effects (588) 588
acute myeloid leukemia (585) 585
toxicity (584) 584
immunology (567) 567
patients (565) 565
drug therapy (564) 564
stem-cell transplantation (554) 554
acute myelogenous leukemia (543) 543
salvage therapy (543) 543
acute myeloid-leukemia (541) 541
stem cells (535) 535
neutropenia - chemically induced (530) 530
clinical trials (526) 526
cyclophosphamide (503) 503
hematopoietic stem cell transplantation (496) 496
leukemia, myeloid, acute - mortality (496) 496
article (495) 495
pediatrics (480) 480
tumors (480) 480
disease progression (478) 478
cyclophosphamide - adverse effects (475) 475
kaplan-meier estimate (475) 475
carcinoma, squamous cell - drug therapy (455) 455
antineoplastic agents (450) 450
induction therapy (443) 443
transplantation, autologous (443) 443
phase-ii (441) 441
breast neoplasms - drug therapy (439) 439
remission (437) 437
randomized-trial (433) 433
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10736) 10736
Japanese (248) 248
Chinese (173) 173
French (79) 79
German (77) 77
Russian (63) 63
Spanish (48) 48
Polish (19) 19
Hungarian (17) 17
Italian (7) 7
Czech (5) 5
Dutch (4) 4
Portuguese (3) 3
Serbian (3) 3
Ukrainian (3) 3
Icelandic (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
by Sun, Ying, Prof and Li, Wen-Fei, MD and Chen, Nian-Yong, Prof and Zhang, Ning, Prof and Hu, Guo-Qing, Prof and Xie, Fang-Yun, Prof and Sun, Yan, Prof and Chen, Xiao-Zhong, Prof and Li, Jin-Gao, Prof and Zhu, Xiao-Dong, Prof and Hu, Chao-Su, Prof and Xu, Xiang-Ying, Prof and Chen, Yuan-Yuan, MD and Hu, Wei-Han, Prof and Guo, Ling, Prof and Mo, Hao-Yuan, Prof and Chen, Lei, MD and Mao, Yan-Ping, MD and Sun, Rui, MD and Ai, Ping, MD and Liang, Shao-Bo, MD and Long, Guo-Xian, MD and Zheng, Bao-Min, MD and Feng, Xing-Lai, MD and Gong, Xiao-Chang, MD and Li, Ling, MD and Shen, Chun-Ying, MD and Xu, Jian-Yu, MD and Guo, Ying, PhD and Chen, Yu-Ming, Prof and Zhang, Fan, MD and Lin, Li, MD and Tang, Ling-Long, MD and Liu, Meng-Zhong, Prof and Ma, Jun, Dr Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1509 - 1520
Summary Background The value of adding cisplatin, fluorouracil, and docetaxel (TPF) induction chemotherapy to concurrent chemoradiotherapy in locoregionally... 
Hematology, Oncology and Palliative Medicine | 5-FLUOROURACIL | CISPLATIN | ONCOLOGY | PROGRESSION-FREE SURVIVAL | INTENSITY-MODULATED RADIOTHERAPY | CLINICAL-TRIALS | COMPARING NEOADJUVANT CHEMOTHERAPY | EXPERIENCE | FLUOROURACIL | DOCETAXEL | NECK-CANCER | Chemoradiotherapy - adverse effects | Nasopharyngeal Carcinoma | Carcinoma | Nasopharyngeal Neoplasms - mortality | Humans | Middle Aged | Nasopharyngeal Neoplasms - therapy | Docetaxel | Male | Cisplatin - administration & dosage | Induction Chemotherapy - adverse effects | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Antimitotic agents | Yuan (China) | Medical colleges | Chemotherapy | Radiation | Antineoplastic agents | Cancer | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
by Ferreri, Andrés J M, Dr and Cwynarski, Kate, MD and Pulczynski, Elisa, MD and Ponzoni, Maurilio, Prof and Deckert, Martina, Prof and Politi, Letterio S, MD and Torri, Valter, MD and Fox, Christopher P, MD and Rosée, Paul La, MD and Schorb, Elisabeth, MD and Ambrosetti, Achille, Prof and Roth, Alexander, MD and Hemmaway, Claire, MD and Ferrari, Angela, MD and Linton, Kim M, PhD and Rudà, Roberta, MD and Binder, Mascha, Prof and Pukrop, Tobias, Prof and Balzarotti, Monica, MD and Fabbri, Alberto, MD and Johnson, Peter, Prof and Gørløv, Jette Sønderskov, PhD and Hess, Georg, MD and Panse, Jens, MD and Pisani, Francesco, MD and Tucci, Alessandra, MD and Stilgenbauer, Stephan, Prof and Hertenstein, Bernd, MD and Keller, Ulrich, Prof and Krause, Stefan W, Prof and Levis, Alessandro, MD and Schmoll, Hans J, MD and Cavalli, Franco, Prof and Finke, Jürgen, Prof and Reni, Michele, MD and Zucca, Emanuele, MD and Illerhaus, Gerald, Prof and IELSG and International Extranodal Lymphoma Study Group (IELSG)
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Infection - chemically induced | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
by Lai-ping Zhong and Chen-ping Zhang and Guo-xin Ren and Wei Guo and William N. William Jr and Jian Sun and Han-guang Zhu and Wen-yong Tu and Jiang Li and Yi-li Cai and Li-zhen Wang and Xin-dong Fan and Zhong-he Wang and Yong-jie Hu and Tong Ji and Wen-jun Yang and Wei-min Ye and Jun Li and Yue He and Yan-an Wang and Li-qun Xu and Bo-song Wang and Merrill S. Kies and J. Jack Lee and Jeffrey N. Myers and Zhi-yuan Zhang
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 744 - 751
Purpose To evaluate induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy versus up-front... 
SURVIVAL | ONCOLOGY | ADVANCED HEAD | NECK-CANCER | OROPHARYNGEAL CANCER | P53 | Mouth Neoplasms - drug therapy | Prospective Studies | Follow-Up Studies | Nausea - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Squamous Cell - surgery | Male | Radiotherapy - adverse effects | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Mouth Neoplasms - radiotherapy | Taxoids - adverse effects | Hematologic Diseases - chemically induced | Induction Chemotherapy - methods | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | Induction Chemotherapy - adverse effects | Taxoids - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucositis - etiology | Mouth Neoplasms - surgery | Radiotherapy - methods | Cisplatin - adverse effects | Alopecia - chemically induced | Aged | Index Medicus | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
by Jean Louis Lefebvre and Yoann Pointreau and Frederic Rolland and Marc Alfonsi and Alain Baudoux and Christian Sire and Dominique de Raucourt and Olivier Malard and Marian Degardin and Claude Tuchais and Emmanuel Blot and Michel Rives and Emile Reyt and Jean Marc Tourani and Lionel Geoffrois and Frederic Peyrade and Francois Guichard and Dominique Chevalier and Emmanuel Babin and Philippe Lang and Francois Janot and Gilles Calais and Pascal Garaud and Etienne Bardet
Journal of Clinical Oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 7, pp. 853 - 859
Purpose To compare the efficacy and safety of induction chemotherapy (ICT) followed by chemoradiotherapy (CRT) or bioradiotherapy (BRT) for larynx preservation... 
TRIAL | HEAD | DESIGN KEY ISSUES | ORGAN PRESERVATION | CISPLATIN | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RADIOTHERAPY | FLUOROURACIL | DOCETAXEL | NECK-CANCER | Laryngeal Neoplasms - radiotherapy | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Carcinoma, Squamous Cell - radiotherapy | Chemoradiotherapy, Adjuvant | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized | Organ Sparing Treatments - methods | Laryngeal Neoplasms - drug therapy | Adult | Female | Laryngeal Neoplasms - physiopathology | Cetuximab | France | Radiotherapy, Adjuvant | Radiotherapy Dosage | Drug Administration Schedule | Treatment Outcome | Carcinoma, Squamous Cell - physiopathology | Induction Chemotherapy - adverse effects | Hypopharyngeal Neoplasms - radiotherapy | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Cisplatin - adverse effects | Aged | Hypopharyngeal Neoplasms - drug therapy | Population Surveillance | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
by Cook, Gordon, Prof and Williams, Cathy, MD and Brown, Julia M, Prof and Cairns, David A, PhD and Cavenagh, Jamie, Prof and Snowden, John A, Prof and Ashcroft, A John, PhD and Fletcher, Marie, BSc and Parrish, Chris, MBBS and Yong, Kwee, Prof and Cavet, Jim, PhD and Hunter, Hanna, MD and Bird, Jenny M, MD and Chalmers, Anna, BSc and O'Connor, Sheila, PhD and Drayson, Mark T, Prof and Morris, Treen C M, Prof and Natl Canc Res Inst Haematooncology and National Cancer Research Institute Haemato-oncology Clinical Studies Group
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 874 - 885
Summary Background Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined.... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | SUPERIORITY | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | IMPACT | METAANALYSIS | ONCOLOGY | CLINICAL-TRIALS | LENALIDOMIDE | SALVAGE THERAPY | INDUCTION | MARROW TRANSPLANTATION | Recurrence | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Consolidation Chemotherapy - methods | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Multiple Myeloma - therapy | Time Factors | Adult | Female | Boronic Acids - administration & dosage | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Bortezomib | Dexamethasone - administration & dosage | Proportional Hazards Models | Thrombocytopenia - chemically induced | Disease Progression | Induction Chemotherapy - adverse effects | Retreatment | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Multiple Myeloma - genetics | Stem Cell Transplantation - adverse effects | Care and treatment | Relapse | Multiple myeloma | Clinical trials | Transplantation | Diseases | Cyclophosphamide | Chemotherapy | Hospitals | Stem cells | Dosage and administration | Product development | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
by Jaaback, Kenneth and Jaaback, Kenneth and Johnson, Nick and Johnson, Nick and Lawrie, Theresa A and Lawrie, Theresa A
The Cochrane database of systematic reviews, ISSN 1469-493X, 01/2016, Volume 2016, Issue 2, pp. CD005340 - CD005340
Background Ovarian cancer tends to be chemosensitive and confine itself to the surface of the peritoneal cavity for much of its natural history. These features... 
SURVIVAL | CARBOPLATIN | CYTOREDUCTIVE SURGERY | Antineoplastic Agents [administration & dosage] | CYCLOPHOSPHAMIDE | Humans | PHASE-III | Infusions, Parenteral | Randomized Controlled Trials as Topic | PACLITAXEL | INTRAVENOUS CISPLATIN | TRIAL | MEDICINE, GENERAL & INTERNAL | STAGE-III OVARIAN | Female | Infusions, Intravenous | CARCINOMA | Ovarian Neoplasms [drug therapy; mortality] | Induction Chemotherapy - methods | Infusions, Parenteral - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Agents - adverse effects | Infusions, Parenteral - methods | Ovarian Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)
by Frikha, M and Auperin, A and Tao, Y and Elloumi, F and Toumi, N and Blanchard, P and Lang, P and Sun, S and Racadot, S and Thariat, J and Alfonsi, M and Tuchais, C and Cornely, A and Moussa, A and Guigay, J and Daoud, J and Bourhis, J and GORTEC
Annals of Oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 731 - 736
Abstract Background Concomitant chemotherapy (CT)-radiotherapy (RT) is a standard of care in locally advanced nasopharyngeal carcinoma (NPC) and a role for... 
Randomized trials | Chemotherapy | Nasopharynx carcinoma | randomized trials | HEAD | PATIENT DATA METAANALYSIS | PLUS CONCURRENT CHEMORADIOTHERAPY | ONCOLOGY | PHASE-II | nasopharynx carcinoma | RADIOTHERAPY | FLUOROURACIL | chemotherapy | DOCETAXEL | Nasopharyngeal Carcinoma - mortality | Chemoradiotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nasopharyngeal Neoplasms - mortality | Docetaxel - adverse effects | Humans | Middle Aged | Induction Chemotherapy - methods | Kaplan-Meier Estimate | Nasopharyngeal Carcinoma - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Induction Chemotherapy - adverse effects | Docetaxel - administration & dosage | Nasopharyngeal Neoplasms - radiotherapy | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Cisplatin - adverse effects | Adult | Female | Nasopharyngeal Carcinoma - drug therapy | Aged | Nasopharyngeal Neoplasms - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
by Vora, Ajay, Prof and Goulden, Nick, PhD and Mitchell, Chris, FRCPCH and Hancock, Jeremy, PhD and Hough, Rachael, MD and Rowntree, Clare, PhD and Moorman, Anthony V, Prof and Wade, Rachel, MSc
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 809 - 818
Summary Background No randomised study has shown whether stratification of treatment by minimal residual disease (MRD) response improves outcome in children... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | AIEOP-BFM | ADOLESCENTS | STRATIFICATION | Cyclophosphamide - administration & dosage | Follow-Up Studies | Consolidation Chemotherapy - methods | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Neoplasm, Residual | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Asparaginase - adverse effects | Vincristine - administration & dosage | Female | Child | Doxorubicin - administration & dosage | Drug Hypersensitivity - etiology | Dexamethasone - administration & dosage | Risk Assessment | Mercaptopurine - administration & dosage | Survival Rate | Pancreatitis - chemically induced | Remission Induction | Cytarabine - administration & dosage | Mucositis - chemically induced | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Adolescent | Methotrexate - administration & dosage | Consolidation Chemotherapy - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group
by Pierre Blanchard and Jean Bourhis and Benjamin Lacas and Marshall R. Posner and Jan B. Vermorken and Juan J. Cruz Hernandez and Abderrahmane Bourredjem and Gilles Calais and Adriano Paccagnella and Ricardo Hitt and Jean-Pierre Pignon and Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 23, pp. 2854 - 2860
Purpose Cisplatin plus fluorouracil (PF) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF)... 
TRIAL | 5-FLUOROURACIL | ONCOLOGY | LARYNX PRESERVATION | PHASE-II | CHEMORADIOTHERAPY | DOCETAXEL | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Induction Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Cisplatin - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Taxoids - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
by Schorb, E and Finke, J and Ihorst, G and Kasenda, B and Fricker, H and Illerhaus, G
BMC CANCER, ISSN 1471-2407, 03/2019, Volume 19, Issue 1, pp. 287 - 7
BackgroundPrimary central nervous system lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS) with rising... 
1ST-LINE TREATMENT | CHEMOIMMUNOTHERAPY | PROGNOSIS | METHOTREXATE | High-dose chemotherapy (HDT) | Primary central nervous system lymphoma (PCNSL) | Elderly patients | INTERNATIONAL EXTRANODAL LYMPHOMA | Autologous stem cell transplantation (ASCT) | RANDOMIZATION | ONCOLOGY | RECURRENT PRIMARY CNS | QUALITY-OF-LIFE | RADIOTHERAPY | NERVOUS-SYSTEM LYMPHOMA | Thiotepa - therapeutic use | Lymphoma, Large B-Cell, Diffuse - drug therapy | Cytarabine - therapeutic use | Humans | Antineoplastic Protocols | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Central Nervous System Neoplasms - therapy | Cytarabine - adverse effects | Methotrexate - therapeutic use | Combined Modality Therapy - adverse effects | Induction Chemotherapy - adverse effects | Methotrexate - adverse effects | Rituximab - therapeutic use | Lymphoma, Large B-Cell, Diffuse - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Hematopoietic Stem Cell Transplantation - adverse effects | Transplantation, Autologous - adverse effects | Aged | Central Nervous System Neoplasms - drug therapy | Rituximab - adverse effects | Thiotepa - adverse effects | Chemotherapy | Usage | Care and treatment | Nervous system cancer | Stem cells | Aged patients | Transplantation | Diagnosis | Health aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
by Kang, Hyoung Jin, MD and Loftus, Susan, BSN and Taylor, Arlene, MS and DiCristina, Cara, MPH and Green, Stuart, Dr and Zwaan, Christian Michel, MD
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 385 - 394
Summary Background Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other anti-emetic agents for the prevention of... 
Hematology, Oncology and Palliative Medicine | DEXAMETHASONE | ANTIEMETICS | ANTAGONIST APREPITANT | RECEPTOR ANTAGONISTS | EFFICACY | ONCOLOGY | TOLERABILITY | PEDIATRIC ONCOLOGY PATIENTS | PLACEBO-CONTROLLED TRIAL | HIGH-DOSE CISPLATIN | EMESIS | Double-Blind Method | Nausea - chemically induced | Humans | Morpholines - administration & dosage | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Vomiting - drug therapy | Induction Chemotherapy - adverse effects | Neoplasms - drug therapy | Vomiting - chemically induced | Adolescent | Adult | Female | Nausea - pathology | Vomiting - pathology | Drug-Related Side Effects and Adverse Reactions - drug therapy | Nausea - drug therapy | Neoplasms - pathology | Child | Morpholines - adverse effects | Clinical trials | Chemotherapy | Nausea | Gastrointestinal agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Short and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
by Strober, Bruce, MD, PhD and Leonardi, Craig, MD and Papp, Kim A., MD, PhD, FRCPC and Mrowietz, Ulrich, MD and Ohtsuki, Mamitaro, MD, PhD and Bissonnette, Robert, MD, MSc, FRCPC and Ferris, Laura K., MD, PhD and Paul, Carle, MD, PhD and Lebwohl, Mark, MD, FAAD and Braun, Daniel K., MD, PhD and Mallbris, Lotus, MD, PhD and Wilhelm, Stefan, MD and Xu, Wen, PhD and Ljungberg, Anders, MD and Acharya, Nayan, MBBS, MRCP, MFPM and Reich, Kristian, MD, PhD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 3, pp. 432 - 440.e17
Background Safety of biologics is important when treating patients with psoriasis. Objective We sought to determine the safety of ixekizumab in psoriasis.... 
Dermatology | ixekizumab | etanercept | integrated analysis | psoriasis | safety | interleukin-17A | adverse events | TO-SEVERE PSORIASIS | MODERATE | EFFICACY | USTEKINUMAB | PHASE-III | OPEN-LABEL | MAINTENANCE THERAPY | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | DERMATOLOGY | PLAQUE PSORIASIS | DOUBLE-BLIND | Crohn Disease - epidemiology | Myocardial Infarction - chemically induced | Myocardial Infarction - epidemiology | Humans | Middle Aged | Candidiasis - epidemiology | Male | Colitis, Ulcerative - epidemiology | Dermatologic Agents - adverse effects | Incidence | Maintenance Chemotherapy - adverse effects | Neoplasms - chemically induced | Stroke - chemically induced | Time Factors | Crohn Disease - chemically induced | Adult | Female | Stroke - epidemiology | Candidiasis - chemically induced | Antibodies, Monoclonal, Humanized - adverse effects | Etanercept - adverse effects | Psoriasis - drug therapy | Clinical Trials as Topic | Induction Chemotherapy - adverse effects | Colitis, Ulcerative - chemically induced | Neoplasms - epidemiology | Psoriasis | Clinical trials | Pharmaceutical industry | Etanercept | Interleukins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
by Chen, Allen M, Prof and Felix, Carol and Wang, Pin-Chieh, PhD and Hsu, Sophia, RN and Basehart, Vincent and Garst, Jordan and Beron, Phillip, MD and Wong, Deborah, MD and Rosove, Michael H, Prof and Rao, Shyam, MD and Melanson, Heather and Kim, Edward, MD and Palmer, Daphne, MD and Qi, Lihong, PhD and Kelly, Karen, Prof and Steinberg, Michael L, Prof and Kupelian, Patrick A, Prof and Daly, Megan E, MD
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 803 - 811
Summary Background Head and neck cancers positive for human papillomavirus (HPV) are exquisitely radiosensitive. We investigated whether chemoradiotherapy with... 
Hematology, Oncology and Palliative Medicine | TRIAL | SURVIVAL | ORGAN PRESERVATION | THERAPY | ONCOLOGY | POSITIVE HEAD | RISK | LOCALLY ADVANCED HEAD | RADIATION | NECK-CANCER | CHEMOTHERAPY | Chemoradiotherapy - adverse effects | Follow-Up Studies | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Oropharyngeal Neoplasms - pathology | Carcinoma, Squamous Cell - radiotherapy | Human papillomavirus 16 | Neoplasm Metastasis | Leukopenia - chemically induced | Deglutition Disorders - etiology | Papillomavirus Infections - virology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Radiotherapy Dosage | Oropharyngeal Neoplasms - drug therapy | Papillomavirus Infections - complications | Carboplatin - administration & dosage | Oropharyngeal Neoplasms - radiotherapy | Survival Rate | Neoplasm Recurrence, Local - diagnosis | Oropharyngeal Neoplasms - virology | Induction Chemotherapy - adverse effects | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucositis - etiology | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Staging | Papillomaviruses | Carcinoma | Radiotherapy | Papillomavirus infections | Radiation | Cancer | Medical research | Chemotherapy | Analysis | Medicine, Experimental
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights